Resistance looms for KRASG12C inhibitors

Cells develop a heterogeneous response to KRAS inhibitors, bypassing their anti-growth effects by producing more of the protein that does not bind the inhibitor.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: The disparate responses to KRAS inhibitors in lung cancer.


  1. 1.

    Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).

    CAS  Article  Google Scholar 

  2. 2.

    Canon, J. et al. Nature 575, 217–223 (2019).

    CAS  Article  Google Scholar 

  3. 3.

    Hallin, J. et al. Cancer Discov. (2019).

    Article  Google Scholar 

  4. 4.

    Ruess, D. A. et al. Nat. Med. 24, 954–960 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Mainardi, S. et al. Nat. Med. 24, 961–967 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Misale, S. et al. Clin. Cancer Res. 25, 796–807 (2019).

    Article  Google Scholar 

  7. 7.

    Xue, J.Y. et al. Nature (2020).

    Article  Google Scholar 

  8. 8.

    Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).

    CAS  Article  Google Scholar 

  9. 9.

    Patricelli, M. P. et al. Cancer Discov. 6, 316–329 (2016).

    CAS  Article  Google Scholar 

  10. 10.

    Prahallad, A. et al. Nature 483, 100–103 (2012).

    CAS  Article  Google Scholar 

  11. 11.

    Shaffer, S. M. et al. Nature 546, 431–435 (2017).

    CAS  Article  Google Scholar 

  12. 12.

    Hata, A. N. et al. Nat. Med. 22, 262–269 (2016).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Aaron N. Hata or Alice T. Shaw.

Ethics declarations

Competing interests

A.N.H. has received research funding from Amgen, Pfizer, Roche/Genentech, Eli Lilly, Novartis and Relay Therapeutics. A.T.S. has served as a compensated consultant or received honoraria from Achilles, Archer, ARIAD, Bayer, Blueprint Medicines, Chugai, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Guardant, Ignyta, KSQ Therapeutics, LOXO, Natera, Novartis, Pfizer, Servier, Syros, Taiho Pharmaceutical, Takeda and TP Therapeutics; has received research (institutional) funding from Daiichi Sankyo, Ignyta, Novartis, Pfizer, Roche/Genentech and TP Therapeutics; has served on the Board of Directors of Syros Pharmaceuticals; and is currently an employee of Novartis.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hata, A.N., Shaw, A.T. Resistance looms for KRASG12C inhibitors. Nat Med 26, 169–170 (2020).

Download citation

Further reading